|Bid||40.77 x 900|
|Ask||63.55 x 900|
|Day's Range||60.32 - 64.18|
|52 Week Range||33.10 - 71.11|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 02, 2020 - Nov 06, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||73.00|
Blueprint Medicines on Tuesday reported positive test results for its treatment for a potentially fatal rare disease, sending BPMC stock to a 13-month high extending beyond a buy zone.
How far off is Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) from its intrinsic value? Using the most recent financial...
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), today announced the presentation of nine month follow-up data from the Company’s Phase 3 INVICTUS study of QINLOCK in patients with fourth-line and fourth-line plus gastrointestinal stromal tumors (GIST) and intra-patient dose escalation data from the ongoing Phase 1 study of QINLOCK in patients with second-line through fourth-line plus GIST. The mini-oral presentations, titled "Clinical Benefit with Ripretinib as ≥4th Line Treatment in Patients with Advanced Gastrointestinal Stromal Tumors (GIST): Update from the Phase 3 INVICTUS Study" and "Ripretinib Intra-patient Dose Escalation (IPDE) Following Disease Progression Provides Clinically Meaningful Progression-Free Survival (PFS) in Gastrointestinal Stromal Tumor (GIST) in Phase 1 Study", were featured at the ESMO Virtual Congress 2020 being held September 19-21, 2020.